LIVOPT -- LIVer cirrhosis - Optimizing Prediction of Patient OuTcomes
LIVOPT——肝硬化——优化患者结果的预测
基本信息
- 批准号:10490243
- 负责人:
- 金额:$ 63.51万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-30 至 2026-05-31
- 项目状态:未结题
- 来源:
- 关键词:AffectAreaAscitesAttentionBlack raceCaringCause of DeathCessation of lifeChicagoCirrhosisClinicalCountyDataData SetDevelopmentDiagnosisDisease ProgressionDisease modelElderlyElectronic Health RecordEpidemiologyEventGastrointestinal HemorrhageGraphHealth systemHepatic EncephalopathyHospitalizationInfectionInpatientsInsuranceIntensive CareInterventionKnowledgeLife ExperienceLiverLiver CirrhosisMachine LearningMedicalModelingOutcomes ResearchPatient RepresentativePatient-Focused OutcomesPatientsPatternPersonsPopulationPrimary carcinoma of the liver cellsPrivatizationProbabilityPublic HealthRaceResearchResourcesRiskRisk EstimateSamplingSampling BiasesSocioeconomic FactorsSubgroupTechniquesTimeTransplantationUnited Network for Organ SharingUnited StatesUnited States Centers for Medicare and Medicaid ServicesUnited States Department of Veterans AffairsWorkadjudicateblack patientcostdata repositorydeep learningdisabilitydisorder riskend stage liver diseasehigh riskimproved outcomemetropolitanmortalitymortality risknovelolder patientorgan allocationpatient populationpatient subsetspopulation basedpredictive modelingrisk predictiontransplant modelyoung adult
项目摘要
PROJECT ABSTRACT
Cirrhosis is a leading cause of mortality in the United States (US), diagnosed in millions of people and resulting
in over 40,000 deaths each year, predominately in older people. These patients are at higher risk of serious
complications (e.g. infection, ascites, hepatic encephalopathy), hospitalization and death. Little is known about
the epidemiology and disease progression and older patients are more vulnerable and might have different risk
profiles. The clinical challenge is to accurately and early predict who is at highest risk for requiring
hospitalization and/or death and understanding how this might be different in older versus younger adults. .
One barrier to date has been the lack of an epidemiologically representative patient sample that captures those
with cirrhosis and goes beyond one health system, as many data repositories are skewed or limited: CMS only
captures elderly and those with debility, NIS does not allow longitudinal observation, UNOS represents less
than one percent of those with cirrhosis. Hence, we will build on our previous work to use a unique dataset, the
Chicago Area Patient-Centered Outcomes Research Network (CAPriCORN). CAPriCORN captures the
electronic health records (EHR) from nine health systems from 2011-present (incl. academic center, county,
VA and private), catching most of the diverse patient population in the greater Chicago metropolitan area,
namely ~160,000 patients with liver cirrhosis. The dataset is extensive, allowing the use of traditional (e.g.,
regression) and novel analytical techniques (e.g. deep learning) to pursue the aims of the study. We aim to
model cirrhosis progression in the elderly and to predict the risk of hospitalization and death in older patients
with cirrhosis. We also aim to perform sub-group analyses focusing on race and socioeconomic factors in the
elderly. The impact of accurate and early prediction of mortality and hospitalization risk in elderly patients with
cirrhosis allows for targeted interventions of the most vulnerable patients to improve outcomes.
项目摘要
肝硬化是美国死亡率的主要原因(美国),被诊断为数百万人,导致
每年超过40,000人死亡,主要是老年人。这些患者的严重风险更高
并发症(例如感染,腹水,肝脑病),住院和死亡。对
流行病学和疾病进展和老年患者更脆弱,风险可能不同
概况。临床挑战是准确和早期预测谁面临最高风险
住院和/或死亡以及了解年龄较大的年轻人可能有何不同。 。
迄今为止的一个障碍是缺乏捕获这些样本的流行病学代表性的患者样本
肝硬化并超越了一个卫生系统,因为许多数据存储库都是偏斜或有限的:仅CMS
NIS捕获老年人和有骨质的人,不允许纵向观察,UNOS代表较少
肝硬化的人中有百分之一。因此,我们将以我们以前的工作为基础,以使用唯一的数据集,
芝加哥地区以患者为中心的结果研究网络(摩ri座)。摩ri座捕获
来自2011年至今的九个卫生系统的电子健康记录(EHR)(包括学术中心,县,
弗吉尼亚州和私人),在大芝加哥大都市地区捕捉大多数多样化的患者人口,
即约160,000名肝硬化患者。数据集很广泛,允许使用传统(例如,
回归)和新颖的分析技术(例如深度学习)来追求研究的目的。我们的目标
模型在老年人中的肝硬化进展,并预测老年患者住院和死亡的风险
与肝硬化。我们还旨在进行侧重于种族和社会经济因素的亚组分析
老年。准确和早期预测死亡率和住院风险对老年患者的影响
肝硬化允许对最脆弱的患者进行有针对性的干预措施,以改善预后。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Daniela P Ladner其他文献
Transforming the Future of Surgeon-Scientists
改变外科医生科学家的未来
- DOI:
- 发表时间:
2023 - 期刊:
- 影响因子:9
- 作者:
Daniela P Ladner;Allan M. Goldstein;Tim Billiar;Andrew M Cameron;Darren R Carpizo;Daniel I Chu;Craig M Coopersmith;Ronald P DeMatteo;Sandy Feng;Katherine A Gallagher;W. Gillanders;B. Lal;G. Lipshutz;Annie Liu;Ronald V. Maier;E. Mittendorf;Arden M. Morris;J. Sicklick;O. Velazquez;Bryan A. Whitson;Lee G Wilke;Sam S Yoon;Martha A. Zeiger;Diana L Farmer;E. S. Hwang - 通讯作者:
E. S. Hwang
Daniela P Ladner的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Daniela P Ladner', 18)}}的其他基金
Natural history, risk prediction and cost of cirrhosis in insured Americans.
受保美国人的肝硬化自然史、风险预测和费用。
- 批准号:
10346703 - 财政年份:2022
- 资助金额:
$ 63.51万 - 项目类别:
Natural history, risk prediction and cost of cirrhosis in insured Americans.
受保美国人的肝硬化自然史、风险预测和费用。
- 批准号:
10557845 - 财政年份:2022
- 资助金额:
$ 63.51万 - 项目类别:
The Northwestern Summer Research Program for Medical Students
西北医学生夏季研究计划
- 批准号:
10090216 - 财政年份:2021
- 资助金额:
$ 63.51万 - 项目类别:
LIVOPT -- LIVer cirrhosis - Optimizing Prediction of Patient OuTcomes
LIVOPT——肝硬化——优化患者结果的预测
- 批准号:
10666608 - 财政年份:2021
- 资助金额:
$ 63.51万 - 项目类别:
The Northwestern Summer Research Program for Medical Students
西北医学生夏季研究计划
- 批准号:
10391427 - 财政年份:2021
- 资助金额:
$ 63.51万 - 项目类别:
Transplant Regimen Adherence for Kidney Recipients by Engaging Information Technologies: The TAKE IT Trial
通过利用信息技术提高肾受者的移植方案依从性:TAKE IT 试验
- 批准号:
9309767 - 财政年份:2017
- 资助金额:
$ 63.51万 - 项目类别:
Transplant Regimen Adherence for Kidney Recipients by Engaging Information Technologies: The TAKE IT Trial
通过利用信息技术提高肾受者的移植方案依从性:TAKE IT 试验
- 批准号:
9906214 - 财政年份:2017
- 资助金额:
$ 63.51万 - 项目类别:
A2ALL- Patient Safety System Improvements in Living Donor Liver Transplantation
A2ALL-活体肝移植中患者安全系统的改进
- 批准号:
8477034 - 财政年份:2011
- 资助金额:
$ 63.51万 - 项目类别:
A2ALL- Patient Safety System Improvements in Living Donor Liver Transplantation
A2ALL-活体肝移植中患者安全系统的改进
- 批准号:
8731865 - 财政年份:2011
- 资助金额:
$ 63.51万 - 项目类别:
A2ALL- Patient Safety System Improvements in Living Donor Liver Transplantation
A2ALL-活体肝移植中患者安全系统的改进
- 批准号:
8188248 - 财政年份:2011
- 资助金额:
$ 63.51万 - 项目类别:
相似国自然基金
跨区域调水工程与区域经济增长:效应测度、机制探究与政策建议
- 批准号:72373114
- 批准年份:2023
- 资助金额:40 万元
- 项目类别:面上项目
农产品区域公用品牌地方政府干预机制与政策优化研究
- 批准号:72373068
- 批准年份:2023
- 资助金额:41 万元
- 项目类别:面上项目
新型城镇化与区域协调发展的机制与治理体系研究
- 批准号:72334006
- 批准年份:2023
- 资助金额:167 万元
- 项目类别:重点项目
我国西南地区节点城市在次区域跨国城市网络中的地位、功能和能级提升研究
- 批准号:72364037
- 批准年份:2023
- 资助金额:28 万元
- 项目类别:地区科学基金项目
多时序CT联合多区域数字病理早期预测胃癌新辅助化疗抵抗的研究
- 批准号:82360345
- 批准年份:2023
- 资助金额:32 万元
- 项目类别:地区科学基金项目
相似海外基金
Identifying determinants of access to the early steps of liver transplant in the Southeast
确定东南部获得肝移植早期步骤的决定因素
- 批准号:
10644293 - 财政年份:2023
- 资助金额:
$ 63.51万 - 项目类别:
Targeting chemotherapy resistant high grade serous ovarian cancer
靶向化疗耐药的高级别浆液性卵巢癌
- 批准号:
10744479 - 财政年份:2023
- 资助金额:
$ 63.51万 - 项目类别:
LIVOPT -- LIVer cirrhosis - Optimizing Prediction of Patient OuTcomes
LIVOPT——肝硬化——优化患者结果的预测
- 批准号:
10666608 - 财政年份:2021
- 资助金额:
$ 63.51万 - 项目类别:
Adrenergic signaling inhibition to enhance the immunogenicity of the ovarian tumor microenvironment prior to PD-1 checkpoint therapy
在 PD-1 检查点治疗之前抑制肾上腺素信号传导以增强卵巢肿瘤微环境的免疫原性
- 批准号:
10056699 - 财政年份:2020
- 资助金额:
$ 63.51万 - 项目类别:
Chemical pancreatectomy for chronic pancreatitis and pancreatic cancer
化学胰腺切除术治疗慢性胰腺炎和胰腺癌
- 批准号:
10163180 - 财政年份:2019
- 资助金额:
$ 63.51万 - 项目类别: